CR20220006A - Compuestos para tratar enfermedad respiratoria - Google Patents

Compuestos para tratar enfermedad respiratoria

Info

Publication number
CR20220006A
CR20220006A CR20220006A CR20220006A CR20220006A CR 20220006 A CR20220006 A CR 20220006A CR 20220006 A CR20220006 A CR 20220006A CR 20220006 A CR20220006 A CR 20220006A CR 20220006 A CR20220006 A CR 20220006A
Authority
CR
Costa Rica
Prior art keywords
respiratory disease
compounds
treating respiratory
treating
tmem16a
Prior art date
Application number
CR20220006A
Other languages
English (en)
Inventor
Stephen Collingwood
Naomi Went
Someina Khor
Duncan Alexander Hay
Albert Ma
Thomas Beauregard Schofield
Edward Walker
Jonathan David Hargrave
Clive Mccarthy
Peter Ingram
Christopher Stimson
Matthew Smith
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1908451.6A external-priority patent/GB201908451D0/en
Priority claimed from GBGB1917691.6A external-priority patent/GB201917691D0/en
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of CR20220006A publication Critical patent/CR20220006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Los compuestos de fórmula general (I) y sus formas tautoméricas, todos los enantiómeros y variantes isotópicas, y sales y solvatos de estos: (I) (AA) en donde representa un enlace simple o un enlace doble y R1 , R2 , X1 , X2 , X3 , X4 , X5 , Y y Z son como se define en la presente; son útiles para el tratamiento de enfermedades respiratorias y otras enfermedades y afecciones moduladas por TMEM16A.
CR20220006A 2019-06-12 2020-06-12 Compuestos para tratar enfermedad respiratoria CR20220006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908451.6A GB201908451D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease
GBGB1917691.6A GB201917691D0 (en) 2019-12-04 2019-12-04 Compounds for treating respiratory disease
PCT/GB2020/051415 WO2020249957A1 (en) 2019-06-12 2020-06-12 Compounds for treating respiratory disease

Publications (1)

Publication Number Publication Date
CR20220006A true CR20220006A (es) 2022-06-06

Family

ID=71120193

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220006A CR20220006A (es) 2019-06-12 2020-06-12 Compuestos para tratar enfermedad respiratoria

Country Status (16)

Country Link
US (1) US20220098167A1 (es)
EP (1) EP3983389A1 (es)
JP (1) JP2022535980A (es)
KR (1) KR20220050126A (es)
CN (1) CN114269721A (es)
AU (1) AU2020290049A1 (es)
BR (1) BR112021025079A2 (es)
CA (1) CA3141394A1 (es)
CL (1) CL2021003275A1 (es)
CO (1) CO2022000084A2 (es)
CR (1) CR20220006A (es)
IL (1) IL288793A (es)
MA (1) MA56186A (es)
MX (1) MX2021015214A (es)
PE (1) PE20221003A1 (es)
WO (1) WO2020249957A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases
JP2023552638A (ja) * 2020-12-11 2023-12-18 ティーエムイーエム１６エー リミテッド 呼吸器疾患を治療するためのベンゾイミダゾール誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615636A1 (en) * 2003-04-10 2006-01-18 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
US7772231B2 (en) * 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
ES2617957T3 (es) * 2007-08-03 2017-06-20 Summit (Oxford) Limited Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2013033269A1 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
EP3612180B1 (en) * 2017-04-17 2023-10-11 The Regents of the University of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CA3111392A1 (en) * 2018-09-04 2020-03-12 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use

Also Published As

Publication number Publication date
EP3983389A1 (en) 2022-04-20
WO2020249957A1 (en) 2020-12-17
MA56186A (fr) 2022-04-20
PE20221003A1 (es) 2022-06-15
CL2021003275A1 (es) 2022-08-19
US20220098167A1 (en) 2022-03-31
JP2022535980A (ja) 2022-08-10
AU2020290049A1 (en) 2022-02-03
CO2022000084A2 (es) 2022-04-08
IL288793A (en) 2022-02-01
MX2021015214A (es) 2022-04-06
BR112021025079A2 (pt) 2022-02-15
CA3141394A1 (en) 2020-12-17
KR20220050126A (ko) 2022-04-22
CN114269721A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12020551327A1 (en) Compounds
MX2017016363A (es) Fenoxifenilamidinas sustituidas con halogeno y el uso de estas como fungicidas.
EP4233910A3 (en) Methods of treatment of cholestatic diseases
MX2018000050A (es) Fenoxihalogenofenilamidinas y su uso como fungicidas.
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
EP3934652A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MX2019005097A (es) Composiciones y metodos para tratar la enfermedad del enverdecimiento de los citricos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021016058A (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20220006A (es) Compuestos para tratar enfermedad respiratoria
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
NZ740817A (en) Pcna inhibitors
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
PH12018500999A1 (en) Sodium channel blocker
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2019000086A (es) Formas cristalinas de un compuesto de tetraciclina sustituido con 9-aminometilo y un metodo para la preparacion de las mismas.
PH12020551206A1 (en) Farber disease markers and uses thereof
CR20220072A (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
BR112021020349A2 (pt) Peixe estéril